Patents Examined by Quang Nguyen
  • Optimised coding sequence and promoter
    Patent number: 10709796
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 14, 2020
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • Multi-indication mRNA cancer immunotherapy
    Patent number: 10682401
    Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: June 16, 2020
    Assignee: MORPHOGENESIS, INC.
    Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous, Michael J. Shamblott
  • Immunostimulatory plasmids
    Patent number: 10683508
    Abstract: The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: June 16, 2020
    Assignee: BAYER ANIMAL HEALTH GMBH
    Inventors: Marc Munnes, Christian Weiss, Elisabeth Feldhues, Romina G. Schauer, Albert Abraham, Andrea Eicker, Hermann Wehlmann
  • Stem cell culture medium and method
    Patent number: 10626366
    Abstract: Stem cells such as embryonic stem cells (ES cells), including human ES cells, are cultured in a medium comprising a ROCK inhibitor, and a stem cell culture medium, optionally serum free, comprises a ROCK inhibitor.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 21, 2020
    Assignee: RIKEN
    Inventors: Yoshiki Sasai, Kiichi Watanabe
  • Nucleic acid vector
    Patent number: 10626413
    Abstract: The present invention provides a nucleic acid vector referred to as pVec constructed through molecular biotechnologies. pVec contains CMV enhancer/promoter, T7 promoter, 5?UTR, MCS, 3?UTR, poly A (120A)-TTATT, BGH poly (A) signal, kanamycin resistance gene and pUC origin, etc. So pVec can be used as a vector for both DNA vaccines or therapeutic drugs and mRNA vaccines or mRNA therapeutic drugs. The 5?UTR, 3?UTR and poly A (120A)-TTATT of pVec can be added to the 5? and 3? ends of the in vitro transcribed mRNA respectively and further stabilize the transcribed mRNA. The present invention also provides the constructed pVec-GM-CSF, pVec-hIL-12 and pVAX1-hIL-12, which are used for evaluating the benefits of pVec.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 21, 2020
    Inventor: Enyu Ding
  • Methods and products for expressing proteins in cells
    Patent number: 10590437
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 17, 2020
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde
  • Genetically modified rat derived from rat embryonic stem cell
    Patent number: 10561122
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: February 18, 2020
    Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • TGIF2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof
    Patent number: 10526577
    Abstract: Disclosed are genetically modified human pancreatic progenitor cells having an exogenous nucleic acid molecule encoding TGIF2, for use as a medicament in the treatment of a subject with diabetes. In addition methods for the production of such cells are described. Also disclosed is an expression vector encoding TGIF2 for use as a medicament in the treatment of a subject with diabetes.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: January 7, 2020
    Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
    Inventors: Francesca Spagnoli, Nuria Cerda-Esteban
  • Synthetic biology-based ADCC technology
    Patent number: 10526392
    Abstract: A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: January 7, 2020
    Assignee: 1GLOBE BIOMEDICAL CO., LTD.
    Inventors: Chiang J. Li, Shyam Unniraman
  • Effective delivery of large genes by dual AAV vectors
    Patent number: 10494645
    Abstract: The present invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5 Kb.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: December 3, 2019
    Assignee: FONDAZIONE TELETHON
    Inventors: Alberto Auricchio, Pasqualina Colella, Ivana Trapani
  • Method of making adenovirus and corresponding plasmids
    Patent number: 10472648
    Abstract: The present disclosure relates to a method of making an adenovirus plasmid comprising a part or all of an adenovirus genome and one or more original restriction sites allowing rapid and flexible manipulation of the adenovirus genome, and methods of preparing adenovirus constructs, for example comprising a transgene. The disclosure also extends to novel intermediates employed in and generated by the method, to plasmids and shuttle vectors of the method and to adenoviruses or adenoviral vectors obtainable from the plasmid and/or method. The disclosure further relates to use of the viruses or vectors, for example obtained from a method disclosed herein, in therapy, such as use in the treatment of cancer.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: November 12, 2019
    Assignee: Psioxus Therapeutics Limited
    Inventors: Alice Claire Noel Brown, Tamara Nicolson
  • Polypeptides, cells, and methods involving engineered CD16
    Patent number: 10464989
    Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: November 5, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Bruce Kenneth Walcheck, Dan Samuel Kaufman, Jianming Wu, Yawu Jing, Zhenya Ni
  • In vitro transcription methods and constructs
    Patent number: 10465190
    Abstract: The present disclosure provides, in some aspects, in vitro transcription systems (including, for example, nucleic acid constructs and polymerases), the use of which increases transcription efficiency while reducing the amount of truncated single-stranded ribonucleic acid transcript produced during an in vitro transcription reaction.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 5, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Jesse Chen, Athanasios Dousis
  • Nucleic acid purification
    Patent number: 10464961
    Abstract: Methods and composition for nucleic acid isolation are provided. In one embodiment, the invention provides a method for nucleic acid purification from biological samples extracted with phenol-based denaturing solvents, which does not require phase separation or nucleic acid precipitation. Methods according to the invention may also be used for differential isolation of RNA and DNA.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: November 5, 2019
    Assignee: ZYMO RESEARCH CORPORATION
    Inventors: Stanislav Forman, Xiyu Jia
  • Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
    Patent number: 10435672
    Abstract: In a method for manufacturing a modified enterovirus of ECHO 7 type by modification of native ECHO 7 virus, isolated by a known method from human feces and identified by genome sequence, the modification is performed initially conducting the virus adaptation in cancer cells, attenuated by anti-cancer agent dacarbazine, further passaging the modified virus in human embryonal fibroblast culture, followed by propagation in human melanoma cells and further passaging in human embryonal fibroblast culture, that was treated by ribavirin, isolation and purification by known method. The modified virus is suitable for treating various tumors.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: October 8, 2019
    Assignee: DITESAN LTD.
    Inventors: Dite Venskus, Ivars Kalvins, Dace Pjanova, Ramona Petrovska, Jurgis Auzins
  • Hybrid proteins and uses thereof
    Patent number: 10435716
    Abstract: There are disclosed hybrid proteins comprising at least one signal sequence; at least one DNA binding domain; and at least one cell penetrating peptide (CPP) domain. In embodiments the CPP domain is a TAT domain, and the DNA binding domain is a HU domain. There is also disclosed the use of the hybrid proteins to introduce exogenous DNA into target cells, and methods for introducing exogenous DNA into target cells using the hybrid proteins.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: October 8, 2019
    Assignee: Symvivo Corporation
    Inventors: Herbert Alexander Graves, Mark Andrew Fox
  • Multimeric coding nucleic acid and uses thereof
    Patent number: 10428349
    Abstract: The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use. In some embodiments, a multimeric coding nucleic acid (MCNA) comprises two or more encoding polynucleotides linked via 3? ends such that the multimeric coding nucleic acid compound comprises two or more 5? ends.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: October 1, 2019
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Michael Heartlein, Daniel Crawford, Shrirang Karve
  • OLIG1 mini-promoters: PIe305
    Patent number: 10426846
    Abstract: Isolated polynucleotides comprising an OLIG1 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, guide RNA, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 1, 2019
    Assignee: University of British Columbia
    Inventors: Elizabeth M. Simpson, Charles de Leeuw, Wyeth W. Wasserman, Daniel Goldowitz
  • Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high throughput screening
    Patent number: 10415057
    Abstract: The invention relates to the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family, genus Morbillivirus, and various uses of the resulting vector particles. The present invention is based on the unexpected and surprising finding that the incorporation of morbillivirus F and H proteins having truncated cytoplasmic tails into lentiviral vector particles, and the complex interaction of these two proteins during cellular fusion, allows for a superior and more effective transduction of cells. Moreover, these pseudotyped vector particles allow the targeted gene transfer into a given cell type of interest by modifying a mutated and truncated H protein with a single-chain antibody or ligand directed against a cell surface marker of the target cell.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 17, 2019
    Assignee: BUNDERSREPUBLIK DEUTSCHLAND, LETZVERTRETEN DURCH DEN PRÄSIDENTEN DES PAUL-EHRLICH-INSTITUTS
    Inventors: Christian Buchholz, Sabrina Kneissl, Klaus Cichutek, Roberto Cattaneo
  • Methods and products for expressing proteins in cells
    Patent number: 10415060
    Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: September 17, 2019
    Assignee: Factor Bioscience Inc.
    Inventors: Matthew Angel, Christopher Rohde